Literature DB >> 10071971

Quality of life issues in the management of ovarian cancer.

L S Fish1, B E Lewis.   

Abstract

In patients with ovarian cancer, quality of life is defined by the severity of the disease. In early stage disease, patients focus on the long-term effects of therapy, whereas in late-stage disease, symptom management is paramount. The chemotherapeutic agents used to combat ovarian cancer have a wide range of adverse effects, the management of which is key to ensuring a patient's quality of life. Patient-specific considerations are also important in maintaining quality of life. However, patient preferences are hard to define and harder to predict, so that it is important to assess each patient individually. A large number of assessment tools have been developed, but many are too cumbersome to administer regularly and provide information that cannot be incorporated into patient care plans. The Functional Assessment of Cancer Therapy questionnaire for ovarian cancer (FACT-O) is a notable exception to this group. The FACT-O is a short questionnaire grouped by logical categories that can be completed by most patients without assistance within 5 minutes. Furthermore, the FACT-O allows patients to weight each category of questions based on the categories' perceived importance to the quality of the patients' lives. These two factors allow the FACT-O to be used to institute management decisions on the level of both the individual patient and the institution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071971

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

Review 1.  Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.

Authors:  David Cella; Sarah K Rosenbloom; Jennifer L Beaumont; Susan E Yount; Diane Paul; Debra Hampton; Amy P Abernethy; Paul B Jacobsen; Karen Syrjala; Jamie H Von Roenn
Journal:  J Natl Compr Canc Netw       Date:  2011-03       Impact factor: 11.908

3.  Quality of life among women after surgery for ovarian cancer.

Authors:  Dena Schulman-Green; Elizabeth Ercolano; Michael Dowd; Peter Schwartz; Ruth McCorkle
Journal:  Palliat Support Care       Date:  2008-09

4.  Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study.

Authors:  Dominique Koensgen; Guelten Oskay-Oezcelik; Ioanna Katsares; Ulla Walle; Christine Klapp; Alexander Mustea; Dirk Stengel; Franz Porzsolt; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2009-09-17       Impact factor: 3.603

5.  Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).

Authors:  Susan Yount; David Cella; Donald Banik; Talat Ashraf; Daniel Shevrin
Journal:  Health Qual Life Outcomes       Date:  2003-11-21       Impact factor: 3.186

6.  Overall Quality of Life Assessment in the Patients Undergoing External Beam Radiation in Outpatient Radiation Oncology Department.

Authors:  Rashmi Koul; Richard Tse; Erwin Karreman; Arbind Dubey; Patricia Tai
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.